Close Menu

lawsuit

The high court has ruled in favor of Roche, saying that just because university-based research may been funded by federal dollars it does not override more than 200 years of patent law and take away the rights to a patent from its inventor.

A Marina official confirmed that neither company paid compensation to the other under the terms of the settlement.

Celera and other defendants have entered into a memorandum of understanding in putative class action lawsuits stemming from the company's proposed acquisition by Quest Diagnostics.

Genetic Technologies said it has secured A$14.5 million ($15.2 million) in licensing revenues since it filed its lawsuit in February 2010.

Genetic Technologies granted a non-exclusive license to Orchid Cellmark for a number of patents covering non-coding analysis, gene mapping, and internal standards.

Alnylam charged that Tekmira has itself violated the companies' agreements by filing the suit, which it said ignores “confidential and non-public alternative dispute resolution procedures required under the … agreements."

Brenda Bass “conceived the inventions of all the issued claims of Tuschl-II and at least some pending claims of Tuschl-I well before any date asserted by the currently named inventors,” the University of Utah alleges.

The New Orleans Employees Retirement System alleges Celera and its board undervalued the company in its $671 million sale to Quest.

In the lawsuit, which comes just days after Alnylam said it settled a different suit related to the IP, the University of Utah alleges that one of its researchers actually invented the technology covered by the Tuschl-II patent estate.

The new offer comes a month after Signal filed suit against Med BioGene for negotiating a licensing deal for the LungExpress Dx test with Precision Therapeutics.

Pages

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.